ALRN - Aileron Therapeutics Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Aileron Therapeutics (ALRN)

Aileron Therapeutics (ALRN) specializes in fibrosis therapy and lung protection for niche medical segments. On GURU.Markets, the ratio of valuation to business expansion rates demonstrates the asset's dynamics, where the indicator value stands at 0.00. Aileron Therapeutics is betting on the uniqueness of its treatment mechanisms, assembling a team of progressive oncologists focused on rapid career growth and concrete trial results.

ALRN: Aileron Therapeutics Price/Earnings to Growth Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Aileron Therapeutics Inc (ALRN)

- market value and analyst target forecast:
Price Rate Chart Aileron|ALRN - Consensus Target
- market capitalization statistics:
Market Value Aileron Therapeutics, Inc.|ALRN - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Aileron Therapeutics|ALRN - Company Net Assets|Market Cap to Book Value Multiple aileronrx.com|ALRN - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Aileron Therapeutics|ALRN - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Aileron Therapeutics, Inc.|ALRN - Company Aggregate Debts|Debt to Net Assets ALRN|ALRN - Company Long-Term Debts|Short-Term Debt Aileron Therapeutics|Intermediate Liquidity Ratio aileronrx.com
- earnings and valuation multiples information:
ALRN - Net Profit|Expected Net Profit Aileron Therapeutics|ALRN - P/E Multiple|Price to Future Earnings Ratio Aileron|ALRN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Aileron Therapeutics, Inc.|ALRN - Operating profit before deduction of amortization|Earnings per share for the last four quarters Aileron Therapeutics|ALRN - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months aileronrx.com|ALRN - Earnings growth in current year|Expected net earnings per share growth next year Aileron Therapeutics
- sales revenue and business income indicators:
ALRN - Company Revenue|Company Future Revenue Aileron Therapeutics, Inc.|ALRN - P/S Multiple|Forward P/S Multiple Aileron Therapeutics
General company analysis:Aileron Therapeutics
Signature product of Aileron Therapeutics, Inc.

By analyzing the PEG ratio (P/E to EPS growth), one can assess the extent to which the market valuation of Aileron Therapeutics (ALRN) is justified by earnings dynamics amid its strategic alliances in oncotherapy. This metric divides the current P/E multiple by the earnings growth rate: a value below one signals that the asset is undervalued, making the biotech company an attractive target for M&A transactions.

Competing companies

Genmab A/S (GMAB) - Price to Net Income Growth Ratio|Exelixis Inc - Price/Earnings to Growth Multiple|Nuvalent (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (IDEAYA Bio)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|ORIC: Company Value to Earnings Growth Ratio|RLAY (Relay Corp) - PEG Multiple|PEG Multiple nurixtx.com|Price/Earnings to Growth Ratio Tyra Biosciences (TYRA)|VSTM (Verastem) - Growth-Adjusted Payback Ratio|PEG Multiple GLUE (Monte Rosa Therapeutics Inc)|Price to Net Income Growth Ratio Cullinan Therapeutics Inc|Immuneering Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate C4 Therapeutics|BDTX (Black Diamond) - Price/Earnings to Growth Multiple|RPTX: Company Value to Earnings Growth Ratio|PMVP (pmvpharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Karyopharm Therapeutics KPTI|PEG Multiple PPCB|Bio Green Med Solution - Growth-Adjusted P/E Ratio|Aadi Bioscience - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks - Company Value to Earnings Growth Ratio